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Abstract Cerebral venous thrombosis (CVT) affects
mainly working-aged individuals. Functional recovery
after CVT is generally considered good with about 3/4 of
patients achieving short-term independence. However,
vascular events, long-term functional outcome, and
employment after CVT remain poorly investigated. We
identified consecutive adult CVT patients treated at the
Helsinki University Hospital (1987–2013) and invited them
to a follow-up visit. Each clinical examination was com-
bined with interview. We also recorded recurrent venous
thromboembolism (VTE) and hemorrhagic events during
follow-up and antithrombotic medication use. A modified
Rankin Scale (mRS) served to assess functional outcome.
Logistic regression served to identify independent factors
associated with unemployment and functional recovery. Of
the 195 patients identified, 21 died, 9 declined to partici-
pate, and 4 were excluded from the study. Thus, 161
patients (106 women) underwent an examination after a
median of 39 months (interquartile range 14–95). VTE
(one of which was CVT) occurred in 9 (6 %) patients, and
severe hemorrhagic events in 10 (6 %). Functional
outcome was good, with 84 % scoring 0–1 on the mRS;
42 % reported residual symptoms. Altogether, 91 (57 %)
patients were employed. After adjusting for age and sex, a
National Institutes of Health Stroke Scale score[2 at
admission and low education level, associated with both
unfavorable functional outcome and unemployment. Long-
term functional outcome after CVT may appear good if
measured with mRS, but patients often have residual
symptoms and are frequently unable to return to their
previous work.
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Introduction
Cerebral venous thrombosis (CVT) is a rare disease that
affects mainly working-aged individuals and is more
common among women. Symptoms of the disease vary:
90 % present with headache, 40 % motor or sensory defi-
cits, and 40 % epileptic seizures. Over half of patients
develop parenchymal lesions [1]. Short-term mortality is
\10 %, and the vast majority of patients regain indepen-
dence in daily living [2, 3].
The largest dataset on outcome after CVT is available
from the International Study on Cerebral Vein and Dural
Sinus Thrombosis (ISCVT), a multinational study with 624
patients monitored over a relatively short period (mean
16 months). That study focused on death and dependency
at the time of follow-up: 8 % died, and 80 % recovered
well (defined as a score of 0–1 on the modified Rankin
Scale (mRS)) [1]. In the ISCVT cohort, the recurrence of
venous thromboembolism was 4/100 patient-years, and
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CVT recurrence was 1.5/100 patient-years [4]. The risk for
thrombotic event recurrence appears to be highest in the
first year after diagnosis [4–6]. Women with a history of
CVT may be at elevated risk for miscarriage, but outcome
does not otherwise differ from that of the general popula-
tion [7, 8]. Relatively few small studies have investigated
long-term outcome (beyond 1–2 years) after CVT [9–15].
Study objectives
The aims of our study were to investigate long-term
functional outcome, residual symptoms, and working
ability after CVT in a large single-center patient popula-
tion. We also explored their risk for recurrent venous
thromboembolism (VTE), antithrombotic medication use,
risk for bleeding events, and reproductive health.
Patients and methods
The appropriate institutional authorities and Ethics Board
approved this study, which was conducted by the Depart-
ment of Neurology, Helsinki University Hospital (HUH).
Our study included all consecutive patients over the age of
16 treated in the HUH area for CVT between January 1987
and August 2013. We invited all patients for a follow-up
visit at least 6 months after diagnosis. Each participant
provided written consent.
Baseline characteristics
We examined patient records extensively and recorded
clinical presentation, etiological and risk factors, laboratory
testing, imaging studies, clinical findings, and treatments.
We also reconstructed the Admission National Institutes of
Health Stroke Scale (NIHSS) and Glasgow Coma Scale
(GCS) from medical records notes. According to our
institutional guidelines, an NIHSS score of 0–2 represented
minor stroke symptoms. We recorded education level in
three categories: primary (compulsory education of 9
years), secondary (high school or equivalent), and tertiary
(university) education. We recorded primary education
only as low education level. We also recorded working
status at the time of CVT diagnosis.
Long-term outcome evaluation
We developed a structured questionnaire to assess long-term
outcome. Questions inquired about education, working sta-
tus, current medication, residual symptoms (epileptic sei-
zures, headache, visual disturbances, motor and sensory
deficits, memory and concentration difficulties fatigue, and
linguistic difficulties) type and duration of anticoagulation
treatment, severe bleeding complications, recurrent venous
thromboembolism, any sickness leading to hospitalization,
and health history. We also recorded the use of oral contra-
ceptives and hormonal replacement therapy, as well as status
of subsequent pregnancies (miscarriages, complications, and
anticoagulation use). Patients also responded to the Beck
Depression Inventory which screens for depression. We
evaluated outcome at least 6 months after initial CVT diag-
nosis in two patients bymailed questionnaires, and in the rest
by questionnaires combined with clinical examination. We
verified all responses and resolved any unclear/equivocal
responses by interviewing patients face-to-face and
reviewing their medical records. Clinical examination
included assessment with the modified rankin scale (mRS),
NIHSS score, and Barthel index.
Main outcome measures
The primary outcome measures were recovery, as mea-
sured with the mRS, and working status at the end of the
follow-up period. A favorable outcome was defined as
mRS 0-1, indicating complete recovery or only mild
residual symptoms not affecting everyday life.
We dichotomized working status as employed and unem-
ployed. We excluded persons who were retired for reasons
unrelated to CVT (old age n = 26; underlying illness n = 9)
from the return-to-work analysis as well as women on
maternity leave (n = 5), due to uncertainty about their ability
to return to their previous employment. We categorized those
working part-time but over 50 % of standard working hours
(n = 2) and students (n = 7) as employed.
Statistical analyses
We considered demographic factors, clinical and imaging
findings, and known risks as possible explanatory factors
for patients’ outcomes. We calculated univariate odds
ratios (OR) and 95 % confidence intervals (CI) for each
individual variable. Binary logistic regression analysis
served to investigate independent factors associated with
unfavorable outcomes and patients’ return to work. We
entered into the multivariate model variables showing a
univariate association with P\ 0.10, and further adjusted
them for age and sex. A two-sided P value\0.05 was
considered significant. SPSS 22 for Windows (Armonk,
NY, USA) served to analyze all data.
Results
We identified 195 consecutive patients with a CVT diag-
nosis. Of these, 21 patients (11 %) died, 9 patients (5 %)
declined to participate, 1 patient moved to another country
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and was lost to follow-up, 1 patient’s CVT diagnosis was
revoked (the final diagnosis was acute cytomegalovirus
infection with sinus hypoplasia), and 2 patients were
excluded due to missing patient records. Thus, 161 patients
remained for examination at follow-up (106 females,
67 %); Fig. 1. The median follow-up period was
39 months (IQR 14-95), yielding a total of 818 patient-
years. The median age at diagnosis was 38 years (IQR
27-54), and at follow-up 45 years (IQR 33-60). The base-
line data on the patients appear in Table 1.
Deceased patients
Of the 21 patients who died, 7 died from direct conse-
quences of the index CVT (4 patients died within 6 months
of diagnosis), 7 from underlying malignancy, 2 from
coronary artery disease, 1 from pulmonary fibrosis, and 1
from dementia; in 3 patients, the cause of death remained
unknown (1 lacked data, 2 were sudden deaths).
Antithrombotic medication, recurrent VTEs,
and hemorrhagic events
In the acute phase, 154 (96 %) patients received heparin, 1
patient began treatment with warfarin, and 5 patients
underwent treatment without anticoagulants. By the end of
the follow-up period, 47 patients (29 %) used no
antithrombotic medication. A total of 56 (35 %) patients
received oral anticoagulants, 9 (6 %) low-molecular-
weight heparin, 40 (25 %) aspirin, and 10 (7 %) patients a
combination of medications; 62 patients (39 %) received
permanent anticoagulation.
Recurrent VTE occurred in nine patients (6 %): five
deep vein thromboses, two pulmonary embolisms, and
three superficial vein thromboses. The incidence of VTE
was 1.1/100 person-years, and CVT recurred in one patient
(incidence 0.1/100 person-years). We noted ten hemor-
rhagic events requiring medical attention, four of which
were potentially life-threatening (4 intracranial bleedings,
2 of which were traumatic), although none was fatal. For
detailed information on thrombotic and bleeding events,
please see Online resource 1.
Reproductive health
During the follow-up period, 23 pregnancies and 5 spon-
taneous miscarriages occurred, but no patients experienced
thrombotic events or complications during pregnancy or
the puerperal period. Only two women did not use
antithrombotic medication during pregnancy (19 patientsFig. 1 Patient flow chart
Table 1 Baseline data on the 161 patients with cerebral venous
thrombosis (CVT)
Demographic data
Female 106 (67)
Age at CVT onset 38 years (24–54)
Follow-up period 39 months (14–95)
Risk factors
Local infection 19 (12)
Malignancy 10 (6)
Any coagulation disorder 34 (21)
Any systemic prothrombotic disorder 25 (16)
Trauma 5 (3)
Neurosurgery 0
No known risk factor 15 (9)
Pregnancy or puerperium in women 5 (3)
Estrogen use in women 39 (24)
Clinical findings at admission
Headache 136 (84)
Motor or sensory deficit 52 (32)
Seizure 49 (30)
Any focal symptom ± encephalopathy 9 (58)
Headache only or IIH* 50 (31)
Glasgow coma scale 12 or lower 10 (6)
NIHSS score[2 31 (19)
Neuroimaging at admission
Infarction 34 (21)
Hemorrhagic lesion 22 (14)
Deep cerebral vein thrombosis 12 (7)
Hydrocephalus 11 (7)
Data appear as n (%) or median (interquartile range)
* Isolated intracranial hypertension
 National Institutes of Health Stroke Scale
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used low-molecular-weight heparin, and 2 patients used
aspirin).
Functional outcome
Functional outcome was good in 82 % of patients scoring
0–1 on the mRS. Modified Rankin scores in different
patient groups appear in Fig. 2. Six patients (4 %) required
assistance in activities of daily living, (scoring below 100
points on the Barthel index). As many as 68 % of patients
reported residual symptoms, the most common of which
were neuropsychological difficulties (41 %), linguistic
difficulties (21 %), headache more than once a week
(20 %), and depression (19 %) (Beck depression inven-
tory[13 points); Table 2.
In univariate analysis, baseline factors associated with
unfavorable outcome (mRS C2) were male sex, low edu-
cation level, focal symptoms, NIHSS score[2, and hem-
orrhagic lesion in magnetic resonance imaging (MRI),
whereas isolated intracranial hypertension or isolated
headache associated with favorable outcome (Table 3). In
female patients, estrogen use (oral contraceptives or hor-
mone replacement therapy) associated with unfavorable
outcome.
After entering the factors with univariate P\ 0.10 into
the logistic regression model and further adjusting them for
age and sex, NIHSS score[2 (OR 5.8, CI 2.2–15.6,
P\ 0.001) and low educational level (OR 4.8, CI
1.3–17.4, P = 0.016) independently associated with unfa-
vorable outcome.
Vocational outcome
At the time of follow-up, 91 (57 %) of patients were
employed. Seven patients (4 %) were employed at the time
of CVT diagnosis, but had retired due to their age. We
found no significant difference in follow-up length between
the employed and unemployed. Factors related to
employment appear in Table 4. In univariate analysis, all
recorded residual symptoms except headache associated
with unemployment. Other factors associated with
employment status were male sex, age[38 years, low
education level, coagulation disorder, and NIHSS
score[2. After adjusting these risk factors for age and sex,
low education (OR 4.8, CI 1.0–21.2, P = 0.046) and
NIHSS score[2 (OR 3.2, CI 1.1–10.9, P = 0.029) asso-
ciated with working status.
Discussion
Our study provides data on various aspects of long-term
outcome in a large singe-center series of CVT patients. The
recurrence risk for VTE was low. Almost all our patients
were independent, and 82 % had a favorable outcome
(mRS 0-1). However, despite apparently good functional
outcome, the majority of our patients reported residual
symptoms.
Fig. 2 Modified rankin scale distribution by selected patient groups.
Asterisk isolated intracranial hypertension, dagger symbol National
Institutes of Health Stroke Scale
Table 2 Thrombotic events, antithrombotic medication and residual
symptoms at follow-up in 161 patients with cerebral venous
thrombosis
Venous thrombotic event recurrence 9 (6)
Recurrent cerebral venous thrombosis 1 (1)
Deep vein thrombosis 5 (3)
Pulmonary embolism 2 (1)
Superficial vein thrombosis 3 (2)
Anticoagulation at follow-up
Permanent anticoagulation in use 62 (39)
Anticoagulation length 6 months (6–12)
No antithrombotic drugs 47 (29)
Low-molecular-weight heparin 9 (6)
Oral anticoagulant (warfarin) 56 (35)
Aspirin 40 (25)
Combination of medications 10 (6)
Hemorrhage requiring medical help 10 (6)
Residual symptoms
Headache[1/week 33 (20)
Motor and/or sensory deficit 11 (6)
Linguistic difficulties 34 (21)
Neuropsychological symptoms, self-reported 66 (41)
Impaired vision 20 (12)
Active epilepsy 15 (9)
Depression 30 (19)
Received neuropsychological rehabilitation 28 (17)
Data appear as n (%) or median (interquartile range)
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Our findings on mortality and functional outcome are
similar to the results of the largest study on CVT study to
date, the ISCVT with\10 % mortality and 80 % of
patients achieving good functional recovery (mRS 0-1).
Dependency (mRS[2) was very rare, with only 2 % of
patients requiring help in daily activities. It is notable that
in our study population, more patients presented with
headache or isolated intracranial hypertension than in the
ISCVT cohort (31 vs. 12 %); parenchymal lesions were
also less common in our study population (33 vs. 63 %).
This difference may be due to greater accessibility to MRI
in recent years, which may have increased the number of
patients presenting with less severe symptoms [1]. Our
findings of age, male sex, and intracerebral hemorrhage in
MRI as predictors of poor functional outcome, and of the
clinical presentation of headache/isolated intracranial
hypertension as a predictor of good functional recovery
confirm those of previous reports [1, 16].
The recurrence of venous thromboembolism in our
study was lower than that observed in previous studies in
which 6 % of patients suffered from VTE (incidence 1.1/
100 patient-years) and CVT recurred only once. The
ISCVT cohort and a smaller study of 154 patients observed
a VTE incidence of 4–5/100 patient-years and a CVT
incidence of 1.5–2.2/100 patient-years [4, 6]. One study
with 145 patients and a six-year follow-up period after
cessation of anticoagulation reported an incidence of CVT
of 0.5/100 patient-years, and of VTE, 2.0/100 patient-
years. However, this study did not include patients with
malignancies or in need of permanent anticoagulation [5].
The low incidence of recurrent VTE in our study may be
due to our patients’ frequent use of antithrombotic drugs, as
39 % of our patients received permanent anticoagulation
medication, and 25 % received aspirin. In previous studies,
the frequency of permanent anticoagulant use was con-
siderably lower (22 and 16 %) [4, 5]. Our institutional
Table 3 Long-term functional outcome in CVT patients
mRS* 0-1 (n = 133) mRS 2-5 (n = 23) OR 95 % CI P
Demographic data
Male sex 39 (29 %) 14 (56 %) 3.07 1.28–7.35 0.009
Age[38 62 (47 %) 17 (68 %) 2.43 0.98–6.02 0.050
Low education level 16 (12 %) 10 (40 %) 4.83 1.86–12.5 0.001
Risk factors
Local infection 18 (14 %) 1 (4 %) 0.27 0.03–2.10 0.181
Malignancy 8 (6 %) 2 (8 %) 1.36 0.27–6.81 0.711
Any systemic disorder 22 (17 %) 3 (12 %) 0.68 0.19–2.48 0.562
Any coagulation disorder 29 (25 %) 5 (24 %) 0.91 0.31–2.69 0.859
Trauma 3 (2 %) 2 (8 %) 3.91 0.62–24.75 0.123
Neurosurgery 0 0 NA NA NA
No known risk factor 11 (15 %) 4 (24 %) 1.65 0.45–6.01 0.450
Pregnancy/puerperium in women 4 (4 %) 1 (9 %) 2.22 0.23–21.90 0.487
Estrogen use in women 31 (33 %) 8 (73 %) 5.33 1.32–21.52 0.010
Clinical findings at admission
Focal symptoms ± encephalopathy 75 (57 %) 19 (79 %) 2.88 1.01–8.20 0.040
Headache only or IIH 47 (35 %) 3 (13 %) 0.25 0.07–0.87 0.029
GCS 12 or lower 7 (5 %) 3 (12 %) 2.56 0.61–16.64 0.190
NIHSS§ score[2 at admission 19 (15 %) 12 (52 %) 6.31 2.40–16.40 \0.001
Neuroimaging at admission
Infarction 27 (20 %) 7 (30 %) 1.53 0.58–4.03 0.393
Hemorrhagic lesion 14 (11 %) 8 (35 %) 4.00 1.46–10.94 0.007
Deep cerebral vein thrombosis 8 (6 %) 4 (16 %) 2.98 0.82–10.80 0.090
Hydrocephalus 2 (2 %) 2 (9 %) 5.70 0.76–42.78 0.090
Intracranial bleeding during anticoagulation treatment 2 (2 %) 2 (9 %) 5.70 0.76–42.48 0.090
* Modified rankin scale
 Isolated intracranial hypertension
 Glasgow coma scale
§ National Institutes of Health Stroke Scale
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guidelines recommend permanent anticoagulation for
patients with recurrent venous thrombosis, thrombophilia,
or a significant non-transient risk factor for venous
thrombosis; for others, guidelines recommend
6–12 months of anticoagulation. No institutional guideli-
nes are available for aspirin use, but doctors often prescribe
aspirin to patients with no obvious or transient risk factors.
Aspirin use may play a role in lowering the incidence of
VTE, as aspirin reduces the risk for venous thrombosis by
42 % [17]. Despite the high number of patients using
anticoagulation medication, only 6 % of them reported
bleeding events requiring medical help (incidence 1.3/100
patient-years). The relatively young age of CVT patients
may explain the low incidence of bleeding events. Notably,
Table 4 Vocational outcome among 121 working-aged patients with cerebral venous thrombosis
Employed (n = 91) Unemployed (n = 30) OR 95 % CI P
Demographic data
Sex, male 22 (24 %) 13 (43 %) 1.28 0.97–1.67 0.048
Age[38 years at CVT* diagnosis 29 (32 %) 17 (57 %) 2.80 1.20–6.52 0.017
Low education level 84 (93 %) 19 (63 %) 6.63 1.11–20.86 0.001
Employed before CVT diagnosis 61 (67 %) 16 (53 %) 2.06 0.86–4.93 0.103
Follow-up period (mean) 60 months 70 months 1.00 1.00–1.01 0.420
Risk factors
Local infection 10 (11 %) 6 (20 %) 2.03 0.67–6.14 0.213
Any infection 12 (13 %) 5 (17 %) 1.32 0.42–4.10 0.635
Malignancy 3 (3 %) 2 (7 %) 2.10 0.33–13.18 0.431
Any systemic disorder 13 (14 %) 4 (13 %) 1.00 0.27–3.04 0.880
Any coagulation disorder 23 (25 %) 2 (7 %) 0.21 0.05–0.96 0.043
Dehydration 12 (13 %) 4 (13 %) 1.00 0.30–3.37 1.000
Trauma 3 (3 %) 1 (3 %) 1.01 0.10–10.11 0.992
Neurosurgery 0 0 NA NA NA
No known risk factor 7 (8 %) 4 (13 %) 2.29 0.56–9.37 0.251
Estrogen use in women 54 (78 %) 9 (53 %) 0.31 0.10–0.95 0.040
Clinical findings at admission
Focal symptoms ± encephalopathy 51 (56 %) 22 (73 %) 2.10 0.85–5.22 0.109
Headache or IIH 35 (38 %) 7 (23 %) 0.51 0.19–1.32 0.163
NIHSS score[2 11 (12 %) 11 (37 %) 4.05 1.53–10.74 0.005
GCS§ 12 or lower 6 (7 %) 2 (7 %) 1.00 0.19–5.24 1.000
Neuroimaging at admission
Infarction 20 (22 %) 9 (30 %) 1.52 0.60–3.83 0.374
Hemorrhagic lesion 8 (9 %) 4 (13 %) 1.59 0.44–5.73 0.473
Deep cerebral vein thrombosis 7 (8 %) 4 (13 %) 1.85 0.50–6.80 0.357
Hydrocephalus 2 (2 %) 3 (10 %) 4.94 0.79–31.14 0.089
Symptoms at follow-up
Headache[1 times/week 9 (10 %) 4 (13 %) 1.01 0.23–4.44 0.983
Motor and/or sensory deficit 4 (4 %) 5 (17 %) 4.53 1.13–18.20 0.033
Linguistic problems, self-reported 12 (13 %) 17 (57 %) 9.33 3.58–24.27 \0.001
Neuropsychological problems, self-reported 21 (23 %) 22 (73 %) 10.48 3.93–27.93 \0.001
Impaired vision 7 (8 %) 7 (23 %) 4.00 1.27–12.65 0.018
Active epilepsy 2 (2 %) 7 (23 %) 29.33 3.42–251.42 0.002
Depression 11 (12 %) 10 (30 %) 3.54 1.31–9.56 0.013
Intracranial bleeding during anticoagulation treatment 2 (2 %) 0 0.00 NA 0.385
* Cerebral venous thrombosis
 Isolated intracranial hypertension
 National Institutes of Health Stroke Scale
§ Glasgow coma scale
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subsequent pregnancies after CVT were uneventful, with
no thrombotic complications. Our findings are in line with
those of previous studies emphasizing that a history of
CVT is no contraindication to future pregnancies [7, 8].
In our study, 68 % of patients reported residual symp-
toms years after their CVT diagnosis. We found a 10 %
rate of active epilepsy, similar to that in previous studies [1,
10, 12]. As many as 20 % of our patients reported suffering
from headache more than once a week; in previous studies,
the prevalence of residual headache has varied widely from
10 to 50 %, depending on the definition [1, 9, 11, 12].
Although a large number of patients reported linguistic and
neuropsychological problems, our study unfortunately
provided no detailed neuropsychological testing. Three
studies with robust cognitive testing showed abnormal
findings in 18–34 % of the patients [13, 14, 18]. In our
study, one in five patients showed signs of depression, thus
supporting the finding of two studies that depression is
common among CVT patients [14, 15]. Our study
strengthens the notion that patients recover well from
paresis, with only one in ten suffering from motor or sen-
sory deficits [10, 12, 14]. Other neurological residual
symptoms, however, were common. Interestingly, we
observed that low education level and an NIHSS score over
two points strongly associated with both incomplete func-
tional recovery and diminished working ability. Education
level may influence motivation and adherence to rehabili-
tation, motivation to return to work, or pose an obstacle to
finding suitable employment. The NIHSS score used in
arterial stroke is reliable clinical measurement method,
showing high correlation with outcome and the size of
parenchymal damage [19]. Our findings that the NIHSS
score also correlates with outcome in CVT suggest that the
NIHSS score could prove useful in early screening of
patients at risk for unfavorable outcome.
Only small studies have previously explored working
ability after CVT. In one study with 34 CVT patients, all
recovered without functional disability and resumed their
work [14]. In two other studies, 20–40 % of CVT patients
failed to resume full-time employment [13, 18]. In our
study, 25 % of working-age CVT patients were unem-
ployed at the end of the follow-up period, and 16 %
received permanent disability pension. Of course, non-
medical issues, such as general economic climate and
national sick retirement benefits and rules, also affect
employment rates. Our study suggests that even though
patients after CVT recover well functionally, residual
symptoms that affect working ability are common.
Our study has strengths and limitations. Our study is
among the largest published single-center series on CVT
outcome thus far, with a respectable follow-up period and a
high participation rate. The study’s weaknesses mainly
arise from its retrospective nature, as the long follow-up
period may have created a selection bias in that early CVT
patients presented with more severe disease. The retro-
spective study design may also have led to reporting bias
on cognitive symptoms and minor bleeding events during
follow-up, so readers should exercise caution with our
conclusions about anticoagulation safety. Another weak-
ness is the study’s lack of neuropsychological testing and
its reliance on patient-reported symptoms.
Conclusions
Our study reinforces the finding that long-term outcome
after CVT is good, with the majority of patients achieving
independence and a low risk for recurrent venous throm-
boembolism with the use of antithrombotic medication.
However, many of our patients suffered from residual
symptoms, and a substantial proportion remained unable to
return to working life.
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